In this study, we report the follow‐up of a patient (II.4, Figure 1) with a germline SMARCB1 deletion of exons 8–9 who survived an AT/RT treated at the age of 2 years without tumor recurrence as determined by analysis of the patient at the age of 17 years (Kordes et al., 2014). Here, SMARCB1 is linked to neoplasm.